Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Conquering Cancer’s Infamous KRAS Mutation

By Sanford Burnham Prebys Medical Discovery Institute | May 15, 2019

KRAS is one of the most challenging targets in cancer. Despite its discovery more than 60 years, researchers still struggle to inhibit its mutated form—earning its reputation as “undruggable.” Yet, the hunt for an Achilles’ heel continues, as cancers driven by KRAS mutations are both common and deadly.

Now, scientists from Sanford Burnham Prebys and PHusis Therapeutics have shown that a compound called PHT-7.3 shrinks KRAS-driven tumors in mice. In contrast to directly targeting mutant KRAS, the potential drug candidate targets the protein’s partner in crime: the cellular scaffold to which mutated KRAS attaches. The study was published in Cancer Research.

“Researchers have successfully developed personalized therapies for other mutations known to drive cancer growth, such as EGFR and BRAF. However, KRAS has remained infamously elusive,” Garth Powis, D.Phil, senior author of the paper, director of Sanford Burnham Prebys’ NCI-designated Cancer Center and scientific co-founder and adviser to PHusis Therapeutics, said. “Our study identifies a promising compound that has the potential to become a much-needed treatment for KRAS-driven cancers, an important advance for the millions of people around the world who are fighting this deadly cancer type.”

KRAS is a protein that regulates cell growth. If it becomes mutated, it can get stuck in the “always on” conformation, leading to the uncontrolled cellular growth that causes cancer. The mutation occurs in approximately 25 percent of all human cancers, including more than 90 percent of pancreatic cancers, 35 to 45 percent of colorectal cancers and approximately 25 percent of lung cancers. There is currently no effective treatment for KRAS-positive cancers.

“Mutated KRAS is firing all the time—similar to speedily typed Morse code versus a calm, intermittent key tap,” Powis explained. “This out-of-control signaling drives tumor growth–and is particularly insidious because it overpowers targeted therapies that may otherwise have been able to treat the cancer.”

In the study, the scientists focused on mutant KRAS’ accomplice, a protein called Cnksr1 (connector enhancer of kinase suppressor of Ras 1). Mutant KRAS floats to the cellular membrane and attaches to this scaffold to become active. After demonstrating that inhibiting Cnksr1 halts the growth of lung and colon cancer cells, the researchers conducted molecular modeling and structural modifications to identify PHT-7.3. This small molecule probe—the starting point for further drug development–shrank KRAS-driven tumors in a mouse model of non-small-cell lung cancer. Importantly, the compound did not affect the function of healthy KRAS—indicating that potential side effects may be limited.

PHT-7.3 is currently undergoing lead optimization activities and preclinical development by PHusis Therapeutics.


Filed Under: Oncology

 

Related Articles Read More >

AstraZeneca
AstraZeneca to scoop up biotech TeneoTwo for up to $1.27 billion
Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia
oncopeptides
Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50